Momelotinib
Brand Names: Ojjaara
Methodology & AI Transparency ⓘ
Momelotinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage ojjaara: is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.
- 2 Real-world patient consensus: 80% patient "Worth It" rating across 4 anonymous logs for Momelotinib (RxNorm 2665210).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $134.05 cash mean against $328.42 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Momelotinib tolerability events: nausea (12.6%), dizziness (6.9%), diarrhea (9.9%).
Ask our AI Specialists anything about Momelotinib
Momelotinib Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage ojjaara: is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. ( 1 )
12.1 Mechanism of Action Momelotinib is an inhibitor of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2 V617F , which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Momelotinib and its major human circulating metabolite, M21, have higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2).
Pharmacokinetic profiling of Momelotinib demonstrates an elimination half-life of Approximately 3–16 hours terminal plasma half-life for Momelotinib with Estimated 72%–84% oral systemic absorption for Momelotinib systemic bioavailability; clearance proceeds via hepatic oxidation via oatp1b1 followed by renal and biliary excretion of momelotinib metabolites, reaching clinical onset within peak plasma concentration (tmax) reached 1–2 hours post-dose for momelotinib.
Titration schedules for Momelotinib (100 mg/1 Tablet → 150 mg/1 Tablet → 200 mg/1 Tablet) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to momelotinib or momelotinib excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-20 momelotinib spl; real-world patient logs highlight nausea (12.6% of reports), diarrhea (9.9% of reports), headache (8.3% of reports) alongside a 80.00% Worth-It consensus.
Potent OATP1B1 modulators alter hepatic clearance of Momelotinib, shifting steady-state plasma concentrations.
Avoid overlapping kinase inhibitor prescriptions alongside Momelotinib to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Momelotinib or Momelotinib excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-20 Momelotinib SPL
Logged Side-Effect Incidence (4 Reports)
Momelotinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Momelotinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Living Longer With Bone Marrow Scarring: What 2,233 Patients Taught Doctors About Ruxolitinib Momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. Leukemia & lymphoma • 2024-07-15 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 38501751 ↗ |
| Living Longer With Bone Marrow Scarring: What 2,233 Patients Taught Doctors About Ruxolitinib These results highlight that both spleen- and anemia-related benefits of momelotinib correlate with improved OS, supporting prioritization of TI in anemic patients for optimal long-term outcomes, and suggest that momelotinib... Clinical lymphoma, myeloma & leukemia • 2026-05-15 • Phase III Randomized Trial | N = 17 | 82/100 | PMID 41813472 ↗ |
Momelotinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.1000/unit (~$93.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $328.42 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $134.05 / mo | View logs ↓ |
| Hone Health Hormone & At-Home Biomarker Lab (Licensed Telehealth Cash Program) | State-licensed clinician review • ~3d mail fulfillment | $65.00 consult | Program details |
| Midi Health Perimenopause & HRT Clinic (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $59.00 consult | Program details |
Momelotinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Momelotinib RxNorm Concept ID | 2665210 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $328.42 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $134.05 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Momelotinib Patient Community, Cohort Filters & Dosage Logs
Cross-verified Momelotinib (kinase inhibitor) monograph synthesizing RxNorm 2665210, openFDA FAERS signals, and $134.05–$328.42 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Momelotinib community threads and patient logs by age, biological sex, dosage, and treatment duration.